AstraZeneca plc (NYSE:AZN) has been given an “A” credit rating by Morningstar. The investment research firm’s “A” rating suggests that the company is a low default risk. They also gave their stock a three star rating.

Other large investors recently added to or reduced their stakes in the company. EisnerAmper Wealth Management raised its stake in AstraZeneca plc by 15.3% in the fourth quarter. EisnerAmper Wealth Management now owns 12,604 shares of the biopharmaceutical company’s stock valued at $428,000 after buying an additional 1,670 shares in the last quarter. EQIS Capital Management raised its stake in AstraZeneca plc by 167.8% in the fourth quarter. EQIS Capital Management now owns 23,264 shares of the biopharmaceutical company’s stock valued at $790,000 after buying an additional 14,578 shares in the last quarter. Finally, Jennison Associates raised its stake in AstraZeneca plc by 45.5% in the third quarter. Jennison Associates now owns 3,906,335 shares of the biopharmaceutical company’s stock valued at $124,300,000 after buying an additional 1,221,321 shares in the last quarter.

Shares of AstraZeneca plc (NYSE:AZN) opened at 31.48 on Monday. The company has a 50-day moving average of $32.86 and a 200 day moving average of $32.74. AstraZeneca plc has a 12 month low of $29.50 and a 12 month high of $36.69. The company has a market cap of $79.58 billion and a PE ratio of 46.99.

AstraZeneca plc (NYSE:AZN) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $1.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.51 by $0.52. The business earned $5.85 billion during the quarter, compared to analyst estimates of $5.90 billion. AstraZeneca plc’s quarterly revenue was down 6.8% compared to the same quarter last year. During the same quarter last year, the company posted $1.05 EPS. On average, analysts anticipate that AstraZeneca plc will post $2.18 earnings per share for the current year.

A number of other research firms also recently issued reports on AZN. JPMorgan Chase & Co. reissued a “neutral” rating on shares of AstraZeneca plc in a report on Wednesday, December 30th. Morgan Stanley reissued a “buy” rating on shares of AstraZeneca plc in a report on Wednesday, December 30th. TheStreet raised shares of AstraZeneca plc from a “hold” rating to a “buy” rating in a report on Monday, November 23rd. BNP Paribas reissued an “outperform” rating on shares of AstraZeneca plc in a report on Monday, November 30th. Finally, Zacks Investment Research raised shares of AstraZeneca plc from a “hold” rating to a “strong-buy” rating and set a $39.00 price target on the stock in a report on Tuesday, December 1st. Three research analysts have rated the stock with a sell rating, six have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $39.00.

AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. The Company’s medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. The Company’s pipeline includes 133 projects, of which 118 are in the clinical phase of development. AstraZeneca operates in over 100 countries.

12 Month Chart for NYSE:AZN

To view more credit ratings from Morningstar, visit www.jdoqocy.comclick-7674909-10651170.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.